A trial looking at gefitinib for people with advanced non small cell lung cancer (1839IL/0709)

Cancer type:

Lung cancer
Non small cell lung cancer

Status:

Results

Phase:

Phase 3

This trial compared best supportive care and a drug called gefitinib (Iressa) with best supportive care alone for people with advanced non small cell lung cancer. It recruited people whose cancer had stopped responding to treatment.

Advanced non small cell lung cancer can be difficult to treat. When this trial was done, earlier research showed that gefitinib could be a useful treatment for this group of patients. Gefitinib is a type of biological therapy called a tyrosine kinase inhibitor.

The aim of this trial was to see how well gefitinib works for people with advanced non small cell lung cancer. And to find out more about the side effects.

Summary of results

The trial team found that gefitinib and best supportive care was no better than best supportive care alone for people with advanced non small cell lung cancer.

1,688 people took part in this trial

  • Two thirds had best supportive care and gefitinib
  • One third had best supportive care and a dummy drug (placebo)

The researchers analysed the results in 2005. They looked at both groups to see how long people lived. They found no difference between the people who had gefitinib and the people who had the dummy drug.

The main side effects of gefitinib were mild and included skin rashes and diarrhoea.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Nick Thatcher

Supported by

AstraZeneca

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 362

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page